A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Status:
Recruiting
Trial end date:
2023-11-23
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to find the recommended dose of LGK974 as a single agent
and in combination with PDR001 that can be safely given to adult patients with selected solid
malignancies that have progressed despite standard therapy or for which no effective standard
therapy exists